Towards Healthcare
Anticancer Drugs Market to Lead USD 401.32 Bn by 2034

Anticancer Drugs Market Trends in Targeted and IV Therapy

According to market projections, the global anticancer drugs market, valued at USD 167.09 billion in 2024, is anticipated to reach USD 401.32 billion by 2034, growing at a CAGR of 9.14% over the next decade. The growing aging population is more susceptible to cancer, increasing the patient pool for anti-cancer drugs. North America led the global market owing to favorable reimbursement policies in the region.

Content

  • Last Updated: 15 October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

The anticancer drugs market is valued at USD 182.37 billion in 2025 and is on track to reach USD 401.32 billion by 2034, witnessing a steady CAGR of 9.14% during the forecast span.

North America is leading the anticancer drugs market share 40% due to the advanced infrastructure for new drug development, rising prevalence of cancer incidence, and growing research & development activities.

Some key players include Roche / Genentech, Novartis, Pfizer, Merck & Co. (MSD), Bristol Myers Squibb (BMS), and AstraZeneca, among others.

Intravenous (IV) administration is the most common, while oral anti-cancer drugs are the fastest-growing due to patient convenience and compliance.

Cancer Patients Aid Association (CPAA), American Cancer Society, U.S. Food and Drug Administration, Indian Cancer Society, clinicaltrials.gov, WHO, JAMA, GOV.UK
Any Questions